Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02668653 · ClinicalTrials.gov registry record · Phase 3
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
A Phase 3 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 3
- Development phase
- 539
- Enrollment target
NCT02668653 is a Phase 3 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 539 participants.
The verdict
NCT02668653, a Phase 3 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 539 participants
- Enrollment target
Study Summary
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML). Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.
Interventions
- DRUG Placebo
- DRUG Chemotherapy
- DRUG Quizartinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 539 participants |
| Start Date | 2016-09-01 |
| Est. Completion | 2023-06-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02668653
The ClinicalTrials.gov registry entry for NCT02668653 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 539 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02668653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02668653 about?
NCT02668653 is a clinical study titled "Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)". Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML). Participants will have an equal chance of receiving quizar...
What is the current status of trial NCT02668653?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 539 participants. The study started on 2016-09-01. Estimated completion is 2023-06-16.
What interventions are being tested in trial NCT02668653?
The interventions under investigation include: Placebo (DRUG), Chemotherapy (DRUG), Quizartinib (DRUG).
Who is sponsoring clinical trial NCT02668653?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.